New antifungal drugs profiled at Manchester fungal disease conference

0 comment(s)

Researchers gathered in Manchester for the Advances Against Aspergillosis international conference have had the first glimpse of new antifungal agents. Problems with toxicity and resistance limit treatment options currently for the millions of patients worldwide who need antifungal therapy each year.

Three new antifungals were profiled: CD101 from Cidara Therapeutics in San Diego, F901318 from F2G in Manchester and PC945 from Pulmocide in London, as well as earlier stage peptides and new antifungal targets.

Open Letter on Disseminated histoplasmosis and AIDS – to key stakeholders tackling the AIDS epidemic

0 comment(s)

The following open letter has been issued by GAFFI:

To the World Health Organisation, UNAIDS, Pan-American Health Organisation, Médecins Sans Frontières, Bill and Melinda Gates Foundation, Drugs for Neglected Diseases Initiative, UNICEF, national public health agencies and governments.